VMA21 Antikörper

Produktnummer ABIN7254226

Produktdetails anti-VMA21 Antikörper

Target: VMA21 (Vacuolar H+-ATPase Homolog (VMA21))

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VMA21 Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Produktmerkmale: Polyclonal Antibody

Aufreinigung: Antigen affinity purification

Immunogen: Synthetic peptide of human VMA21

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IHC 1:150-1:500, IF 1: 50-1:200, ELISA 1:5000-1:240000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 2.6 mg/mL

Buffer: PBS with 0.05 % Sodium azide and 40 % Glycerol, pH 7.4

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Avoid freeze / thaw cycles.

Details zu VMA21

Target: VMA21 (Vacuolar H+-ATPase Homolog (VMA21))

Andere Bezeichnung: VMA21 (VMA21 Produkte)

Hintergrund: This gene encodes a chaperone for assembly of lysosomal vacuolar ATPase. Required for the assembly of the V0 complex of the vacuolar ATPase (V-ATPase) in the endoplasmic reticulum. Associates with the V0 complex of the vacuolar ATPase (V-ATPase). MEAX is a childhood-onset disease characterized by progressive vacuolation and atrophy of skeletal muscle. It is inherited in recessive fashion, affecting boys and sparing carrier females. Onset is in childhood, and patients exhibit weakness of the proximal muscles of the lower extremities, progressing slowly to involve other skeletal muscle groups over time.

UniProt: Q3ZAQ7